<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363363">
  <stage>Registered</stage>
  <submitdate>11/12/2012</submitdate>
  <approvaldate>31/01/2013</approvaldate>
  <actrnumber>ACTRN12613000114741</actrnumber>
  <trial_identification>
    <studytitle>The time course and magnitude of allopurinol effect on serum uric acid in patients with gout</studytitle>
    <scientifictitle>Can a better understanding of time course and magnitude of allopurinol effect on serum uric acid provide the basis for a revised dosing strategy whcih will enable more patients to acheive the clinical target for serum uric acid of &lt; 0.36 mmol/L? </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gout</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is an observational study in patients who are initiating allopurinol for the treatment of gout. Blood sample for the measurement of allopurinol, oxypurinol and uric acid concentrations will be collected on Days 1,2,3,7,14,21 and 28. Patients will be observed for 28 days.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The aim of this study is to collect intensive pharmacokinetic data from the initiation of allopurinol therapy to clarify the time course and magnitude of urate change in relation to the administered dose and to the measured allopurinol and oxypurinol plasma concentrations.</outcome>
      <timepoint>Blood samples for the measurement of allopurinol and oxypurinol plasma concentrations and serum uric acid concentrations will be collected at baseline (prior to allopurinol therapy) and at 10-20 minutes, 20-40 minutes, 40-60 minutes, 1 - 2 hours, 2 - 3 hours, and 3  - 6 hours and 6-9 hours after the first dose of allopurinol. On Day 2 of therapy blood samples will be collected prior to the second dose and 2-10 hours after the dose. ON Days 3, 7, 14, 21 and 28 a single blood sample will be collected 2-10 hours after the daily dose of allopurinol. Note that all patients will be receiving allopurinol as part of normal care. The starting dose of allopurinol will be determined by the Rheumatologist and will vary depending on the patients co-morbidities.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with gout as defined by the American College of Rheumatology Criteria who are initiating allopurinol as part of routine clinical care. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Patients who are unable or unwilling to give written informed consent
2.	Patients taking concurrent losartan, diuretics or uricosuric agents.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/03/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>28/02/2014</anticipatedenddate>
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Otago</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago Research Grant</primarysponsorname>
    <primarysponsoraddress>Research and Enterprise, PO Box 56, University of Otago, Dunedin, NZ 9054</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Otago Research Grant</fundingname>
      <fundingaddress>Research and Enterprise, PO Box 56, University of Otago, Dunedin, NZ 9054</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof Lisa Stamp</othercollaboratorname>
      <othercollaboratoraddress>Department of Medicine, PO Box 4345, University of Otago Christchurch, NZ, 8140</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Murray Barclay</othercollaboratorname>
      <othercollaboratoraddress>Department of Medicine, PO Box 4345, University of Otago Christchurch, NZ, 8140</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Allopurinol is used to treat gout and works by reducing serum urate concentrations. Current prescribing guidelines frequently result in a suboptimal reduction in urate. This project aims to quantify the time course and magnitude of allopurinol effect on serum urate at the initiation of therapy in relation to plasma drug concentrations and dose. Serum urate and plasma drug concentrations will be measured and used to develop a model that will allow us to predict the probability of successful urate lowering under different dosing regimens. This model will be used to develop a revised dosing strategy in future research. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Ethics Committee</ethicname>
      <ethicaddress>Ground floor, Clocktower Building, University of Otago, Dunedin 9054</ethicaddress>
      <ethicapprovaldate>28/11/2012</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/10/2012</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Mr</title>
      <name>Daniel Wright</name>
      <address>School of Pharmacy, University of Otago, PO Box 56, Dunedin , New Zealand 9054
</address>
      <phone>+6434703476</phone>
      <fax>+6434707275</fax>
      <email>dan.wright@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine, University of Otago Christchurch, PO BOX 4345, Christchurch New Zealand 8140</address>
      <phone>+6433640953</phone>
      <fax />
      <email>Lisa.stamp@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine, University of Otago Christchurch, PO BOX 4345, Christchurch New Zealand 8140</address>
      <phone>+6433640953</phone>
      <fax />
      <email>Lisa.stamp@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine, University of Otago Christchurch, PO BOX 4345, Christchurch New Zealand 8140</address>
      <phone>+6433640953</phone>
      <fax />
      <email>Lisa.stamp@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>